%0 Journal Article
%A Fernández-de-Misa, R
%A Hernández-Machín, B
%A Servitje, O
%A Valentí-Medina, F
%A Maroñas-Jiménez, L
%A Ortiz-Romero, P L
%A Sánchez Schmidt, J
%A Pujol, R M
%A Gallardo, F
%A Pau-Charles, I
%A García Muret, M P
%A Pérez Gala, S
%A Román, C
%A Cañueto, J
%A Blanch Rius, L
%A Izu, R
%A Ortiz-Brugués, A
%A Martí, R M
%A Blanes, M
%A Morillo, M
%A Sánchez, P
%A Peñate, Y
%A Bastida, J
%A Pérez Gil, A
%A Lopez-Lerma, I
%A Muniesa, C
%A Estrach, T
%T First-line treatment in lymphomatoid papulosis: a retrospective multicentre study.
%D 2017
%U http://hdl.handle.net/10668/11661
%X Data regarding response to treatment in lymphomatoid papulosis (LyP) are scarce. To assess the daily clinical practice approach to LyP and the response to first-line treatments. This was a retrospective study enrolling 252 patients with LyP. Topical steroids, methotrexate and phototherapy were the most common first-line treatments, prescribed for 35%, 20% and 14% of the patients, respectively. Complete response (CR) was achieved in 48% of treated patients. Eczematous lesions significantly increased relative risk (RR) of not achieving CR (RR = 1.76; 95% CI 1.16-2.11). Overall median time to CR was 10 months (95% CI 6-13 months), and 78% of complete responders showed cutaneous relapse; both results were similar for all treatment groups (P > 0.05). Overall estimated median disease-free survival (DFS) was 11 months (95% CI 9-13 months) but DFS for patients treated with phototherapy was 23 months (95% CI 10-36 months; P  0.05). Overall estimated median disease-free survival (DFS) was 11 months (95% CI 9-13 months) but DFS for patients treated with phototherapy was 23 months (95% CI 10-36 months; P  Current epidemiological, clinical and pathological data support previous results. Topical steroids, phototherapy and methotrexate are the most frequently prescribed first-line treatments. Although CR and cutaneous relapse rates do not differ between them, phototherapy achieves a longer DFS. Presence of Type A LyP and use of topical steroid or methotrexate were associated with an increased risk of early relapse.
%~